CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- Insilico Medicine ('Insilico', 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co., Limited ('Tenacia'), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, today announced that, building on the productive collaboration over the past year, the two parties will further expand and deepen AI-driven R&D collaboration.
Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million
